Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try
Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try
Heron Therapeutics is positioning its drug, Zynrelef, as a way to help patients avoid addictive opioid painkillers following surgery. The extended-release formulation offers analgesic effects over 72 hours when postsurgical pain is most severe and more likely to require pain management medication.
Shares0
The FDA has approved a Heron Therapeutics combination drug developed to treat postsurgical pain and help patients avoid the need for opioid painkillers, a regulatory decision that comes after the agency twice turned down applications from the biotech.
DrFirst, which provides an array of services including telehealth and e-prescribing, received a $50 million equity investment from Sixth Street Growth. The company plans to use the funds to expand its offerings and further connect healthcare stakeholders.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.